Ranpirnase--an antitumour ribonuclease: its potential role in malignant mesothelioma (Q36425940)

14 August 2017

1 reference

title

Ranpirnase--an antitumour ribonuclease: its potential role in malignant mesothelioma (English)

1 reference

14 August 2017

author

Nicholas J. Vogelzang

series ordinal

2

object named as

Nicholas J Vogelzang

1 reference

14 August 2017

Nick Pavlakis

1

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 April 2006

1 reference

Expert Opinion on Biological Therapy

14 August 2017

published in

1 reference

14 August 2017

volume

6

1 reference

14 August 2017

issue

4

1 reference

14 August 2017

page(s)

391-399

1 reference

New developments about the association of SV40 with human mesothelioma

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.4.391

Asbestos and mesothelioma: worldwide trends

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.4.391

Epidemiology, biologic behavior, and natural history of mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.4.391

Multimodality treatment of diffuse malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.4.391

Surgical management of malignant pleural mesothelioma: a systematic review and evidence summary

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.4.391

Integration of multimodality approaches in the management of malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.4.391

Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.4.391

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.4.391

Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Inst

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.4.391

Combination raltitrexed (Tomudex(R))-oxaliplatin: a step forward in the struggle against mesothelioma? The Institut Gustave Roussy experience with chemotherapy and chemo-immunotherapy in mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.4.391

Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.4.391

Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.4.391

Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.4.391

Phase II trial of ZD0473 as second-line therapy in mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.4.391

Biochemistry of frog ribonucleases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.4.391

Comparative molecular modeling and crystallization of P-30 protein: a novel antitumor protein of Rana pipiens oocytes and early embryos

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.4.391

Ribonuclease A variants with potent cytotoxic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.4.391

Glycosylation of onconase increases its conformational stability and toxicity for cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.4.391

Enhancement of vincristine cytotoxicity in drug-resistant cells by simultaneous treatment with onconase, an antitumor ribonuclease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.4.391

Human mesothelioma cells exhibit tumor cell-specific differences in phosphatidylinositol 3-kinase/AKT activity that predict the efficacy of Onconase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.4.391

Ribonucleases as a novel pro-apoptotic anticancer strategy: review of the preclinical and clinical data for ranpirnase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.4.391

Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.4.391

Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.4.391

21 January 2018

Identifiers

DOI

10.1517/14712598.6.4.391

1 reference

14 August 2017

1 reference